AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 52 min read$TEM

Fukushima Ryan sold $1.1M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 23,818 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $46.19 ($43.25–$46.94, $1.10M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest disclosed fact is the $1.10M open-market sale executed across five trades on 2026-08-03 under a pre-arranged 10b5-1 plan, filed on 2026-08-05.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is routine 10b5-1 selling with no accompanying operational or financial update.

03

What to watch

The filing notes indirect holdings and post-transaction share count, but provides no rationale for the sale; without follow-on buys or guidance changes, trading impact is likely limited.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05, covering sales executed 2026-08-03.

Background

The article is an SEC Form 4 insider transaction report for Tempus AI, Inc. (TEM) by CEO, Data Fukushima Ryan.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO Fukushima Ryan sold $1.10M of TEM shares via a 10b5-1 plan, with weighted-average prices $46.19 across five trades.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity management rather than bearish expectations, so any price reaction may be overstated.

Key entities

  • issuer
    Tempus AI, Inc.

    Subject of the Form 4 insider sale disclosure (TEM).

  • insider
    Fukushima Ryan

    CEO, Data who executed the indirect open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

benzinga.com4 min
AUG 3
$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

investing.com3 min
JUL 31
$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

yahoo.com5 min
JUL 31
$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

scanx.trade5 min
JUL 30
$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.

scanx.trade5 min